CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Omni Bio Pharmaceutical, Inc. is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Omni Bio Pharmaceutical, Inc.
181 W Boardwalk Drive
Unit 202
Phone: (970) 237-5178p:970 237-5178 Fort Collins, CO  80525-3033  United States
This company is no longer actively traded on any major stock exchange.
Business Summary
Omni Bio Pharmaceutical, Inc. is a biopharmaceutical company. The Company is focused on exploring methods of use of alpha-1 antitrypsin (AAT), also referred to as plasma-derived AAT (p-AAT). AAT is a naturally occurring protein that is essential for normal liver and lung function and has been purified from human blood (p-AAT) to treat patients suffering from emphysema due to AAT-deficiency. AAT is purified from human blood and has found to have significant anti-inflammatory, immunomodulatory and tissue protective effects in various animal models of human disease. The Company's clinical data have emerged showing p-AAT's potential utility in the treatment of Type 1 diabetes, post-myocardial infarction heart disease and Graft versus Host Disease (GvHD). The Company's focus on research and development efforts is advancing its first recombinant molecule, AAT and an Fc component of immunoglobulin (AAT-Fc 2) into clinical trials.
(Source: 10-Q)

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
-Yes-----

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
12/31/20143/31/2014YesYes---

Industries
SIC Code Description
2836 Biological products, except diagnostic substances
6163 Loan brokers

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Chief Financial Officer Bruce E.Schneider 63 6/24/2015 1/1/2013
Chief Development Officer Bruce D.Forrest 5/1/2014 5/1/2014
Director JohnRiccardi 51 6/24/2015 9/1/2014

Business Names
Business Name
AAFS
OMBP
Omni Bio Operating, Inc.

General Information
Number of Employees: 1 (As of 3/31/2014)
Outstanding Shares: 40,462,602 (As of 2/17/2015)
Shareholders: 431
Stock Exchange: OTC
Federal Tax Id: 208097969


Copyright © 2023 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Friday, July 21, 2023